• CD28 targeting
  • How it works

Pipeline

Bispecific antibody programs

Bispecific antibody programs

Multispecific antibody programs

Monoclonal antibody programs

Monoclonal antibody programs

Multispecific antibody programs

Back

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn